[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 389
Citations 0
Comment & Response
March 5, 2014

Underrepresentation of Older Adults in Cancer Trials

Author Affiliations
  • 1Yale Primary Care Internal Medicine Residency Program, Yale School of Medicine, New Haven, Connecticut
  • 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2014;311(9):965-966. doi:10.1001/jama.2013.286454

To the Editor We share the concern expressed by Dr Hurria and colleagues1 in their Viewpoint regarding the underrepresentation of older adults in cancer trials submitted for registration with the US Food and Drug Administration (FDA). We disagree with the Institute of Medicine’s (IOM) recommendation to “amend patent law to provide patent extensions of up to six months for companies that conduct clinical trials”2 in this population. The Pediatric Research Equity Act, which provides 6 months of market exclusivity for manufacturers that study their products in children and which serves as the basis for this recommendation, has a more complex legacy than Hurria et al1 acknowledged.

First Page Preview View Large
First page PDF preview
First page PDF preview
×